Independent validation of an adapted neoadjuvant rectal score in breast cancer: a retrospective cohort study

The prognostic reproducibility and incremental value of the breast-cancer-adapted neoadjuvant rectal (NAR) score remain uncertain. We evaluated the published cutoff and its contribution beyond postoperative ypT and ypN, together with exploratory analyses of four pretreatment blood-based indices. This retrospective cohort included 237 women treated between 2016 and 2023. The published NAR cutoff was applied without re-estimation: NAR-low (NAR-L), ≤ 28.35; NAR-high (NAR-H), > 28.35. Surgery-origin distant metastasis-free survival (DMFS) and overall survival (OS) were analyzed using Cox models with administrative censoring on July 15, 2026. Nested model comparisons, paired bootstrap confidence intervals for discrimination, proportional-hazards diagnostics, parsimonious models, and exploratory subtype analyses were performed. Pretreatment blood-based indices were assessed for pathologic response and survival. Breast pathologic complete response (pCR) occurred in 49 patients (20.7%). Median follow-up was 61.9 months. All 237 patients were evaluable for DMFS and OS, including 137 NAR-L and 100 NAR-H patients. NAR-H was associated with shorter DMFS (hazard ratio [HR] 2.68, 95% confidence interval [CI] 1.60–4.50) and OS (HR 4.58, 95% CI 2.15–9.74). Adding NAR to ordinal ypT + ypN models did not demonstrate improved fit ( p = 0.379 and p = 0.807). Changes in Harrell’s C were − 0.004 (− 0.014 to 0.015) for DMFS and − 0.004 (− 0.013 to 0.021) for OS (95% CIs). NAR associations persisted in parsimonious models. Subtype interaction tests were inconclusive. Blood-based indices showed little discrimination for breast pCR, and availability of the C-reactive protein-albumin-lymphocyte index differed by treatment period and response. The adapted NAR cutoff was associated with postoperative outcomes, but incremental value beyond ypT and ypN was not demonstrated. NAR is best interpreted as a post-neoadjuvant prognostic summary; clinical utility and subtype-specific performance require further evaluation.

Authors

Institutions

Publication Details

Journal
World Journal of Surgical Oncology
Published
2026-11-20
DOI
https://doi.org/10.1186/s12957-026-04665-0
Primary Topic
Breast Cancer Treatment Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Independent validation of an adapted neoadjuvant rectal score in breast cancer: a retrospective cohort study

Atilla Çelik, Osman Bilgin Gülçiçek, Nihat Buğdaycı, S. Coban et al.
2 links
World Journal of Surgical Oncology
Breast Cancer Treatment Studies
article

Independent validation of an adapted neoadjuvant rectal score in breast cancer: a retrospective cohort study

Atilla Çelik, Osman Bilgin Gülçiçek, Nihat Buğdaycı, S. Coban, Ahmet Sencer Ergin, Ali Karabulut, Alparslan Saylar, Onur Çakır, İbrahim Doğan
article en

Abstract

The prognostic reproducibility and incremental value of the breast-cancer-adapted neoadjuvant rectal (NAR) score remain uncertain. We evaluated the published cutoff and its contribution beyond postoperative ypT and ypN, together with exploratory analyses of four pretreatment blood-based indices. This retrospective cohort included 237 women treated between 2016 and 2023. The published NAR cutoff was applied without re-estimation: NAR-low (NAR-L), ≤ 28.35; NAR-high (NAR-H), > 28.35. Surgery-origin distant metastasis-free survival (DMFS) and overall survival (OS) were analyzed using Cox models with administrative censoring on July 15, 2026. Nested model comparisons, paired bootstrap confidence intervals for discrimination, proportional-hazards diagnostics, parsimonious models, and exploratory subtype analyses were performed. Pretreatment blood-based indices were assessed for pathologic response and survival. Breast pathologic complete response (pCR) occurred in 49 patients (20.7%). Median follow-up was 61.9 months. All 237 patients were evaluable for DMFS and OS, including 137 NAR-L and 100 NAR-H patients. NAR-H was associated with shorter DMFS (hazard ratio [HR] 2.68, 95% confidence interval [CI] 1.60–4.50) and OS (HR 4.58, 95% CI 2.15–9.74). Adding NAR to ordinal ypT + ypN models did not demonstrate improved fit ( p = 0.379 and p = 0.807). Changes in Harrell’s C were − 0.004 (− 0.014 to 0.015) for DMFS and − 0.004 (− 0.013 to 0.021) for OS (95% CIs). NAR associations persisted in parsimonious models. Subtype interaction tests were inconclusive. Blood-based indices showed little discrimination for breast pCR, and availability of the C-reactive protein-albumin-lymphocyte index differed by treatment period and response. The adapted NAR cutoff was associated with postoperative outcomes, but incremental value beyond ypT and ypN was not demonstrated. NAR is best interpreted as a post-neoadjuvant prognostic summary; clinical utility and subtype-specific performance require further evaluation.

World Journal of Surgical Oncology
Bağcılar Eğitim ve Araştırma Hastanesi (TR)
Good health and well-being
Breast Cancer Treatment Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon